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Abstract
Background: Asthma affects the lives of hundred million people around the World. Despite notable progresses in
disease management, asthma control remains largely insufficient worldwide, influencing patients’ wellbeing and
quality of life. Poor patient handling of inhaling devices has been identified as a major persistent problem that
significantly reduces inhaled drugs’ efficacy and is associated with poor adherence to treatment, impairing clinical
results such as asthma control and increasing disease-related costs. We herein review key research and
development (R&D) innovation in inhaler devices, highlighting major real-world critical errors in the handling and
inhalation technique with current devices and considering potential solutions. Furthermore, we discuss current
evidence regarding breath-triggered inhalers (BTI).
Main body: The two most common significant problems with inhalers are coordinating actuation and inhalation
with pressurized metered-dose inhalers (pMDIs), and the need to inhale forcibly with a dry powder inhaler. BTI R&D
plans were designed to overcome these problems. Its newest device k-haler® has several other important features,
generating a less forceful aerosol plume than previous pMDIs, with efficient drug delivery and lung deposition,
even in patients with low inspiratory flow. The local and systemic bioavailability of fluticasone propionate and
formoterol (FP/FORM) administered via k-haler® has been shown to be therapeutically equivalent when
administered via the previous FP/FORM pMDI. This device requires very few steps and has been considered easy to
use (even at first attempt) and preferred by the patients in a randomized crossover study. In our country, FP/FORM
k-haler is available without additional costs compared to FP/FORM pMDI. All devices continue to require education
and regular checking of the correct inhalation technique.
Conclusion: BTI R&D can bring advantage over current available inhalers, avoiding the two most common
identified critical errors in inhalation technique. K-haler® BTI is currently available, without an increased cost, and
approved for adolescents and adults with asthma in whom treatment with inhaled combined therapy with long-
acting beta2-agonists and corticosteroids is indicated. Its attractive and practical design to facilitate its use has been
awarded. K-haler® represents added value through innovation to fulfill actual asthma patient needs, thus with
potential relevant impact in asthma management and effective control.
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Background
Asthma affects the lives of several hundred million
people around the World, across all age groups, and
strongly influences the wellbeing and quality of life of
patients [1]. The primary goal of management is to
achieve asthma control; this mainly consists of two do-
mains, symptoms control and reduced future risk of ad-
verse outcomes, that are not independent (e.g., well-
controlled asthma symptoms significantly reduce future
risk of adverse outcomes). Given asthma symptoms’
characteristic variability, asthma management requires
regular control assessment, in a close partnership be-
tween patients and physicians and other healthcare pro-
fessionals (HCPs), empowering patients to actively
achieve total disease control as a goal. Pharmacological
treatments mainly consist of inhaled drugs, allowing effi-
cacy and significantly reducing systemic side effects, be-
ing the most efficacious treatments in asthma [1, 2].
Education for health, involving the asthmatic patient
and/or caregivers, goes along with other measures to en-
hance abilities for the inhalation technique and to im-
prove adherence to treatment [1, 2]. In fact, lack of
adherence to treatment in asthma occurs in more than
half of all medical prescriptions, as in other chronic dis-
eases [2]. However, in asthma and other chronic respira-
tory diseases, this reduced adherence to treatment allies
to an incorrect inhalation technique, both considered re-
lated major issues that significantly impair pharmaco-
logic treatments effectiveness [2, 3]. Therefore, despite
the efficacy of the available drugs, a high percentage of
asthmatics are uncontrolled and have frequent
exacerbations.
According to a previous World Health Organization
report, interventions that increase adherence to treat-
ment, simplifying it, may have a greater impact than ac-
cess to new drugs. The adequate knowledge of the
barriers to a correct adhesion can allow preventing its
occurrence [4].
Nowadays, a broad range of inhalers is available for
asthma treatment. Still, many patients with asthma do
not use their inhaler correctly [1, 5–9]. Difficulties in
using inhalation methods are well-known problems that
have been consistently maintained in recent decades.
Several errors affect treatment results with the use of
both dry powder inhalers (DPIs) and pressurized
metered-dose inhalers (pMDIs) [5, 6]. This significantly
reduces the amount of drug that is deposited in the air-
ways [10–12], and is clearly associated with poor asthma
control [13–18].
Results from the Critikal study analyses of the inhaler
technique assessment initiative Helping Asthma in Real-
life Patients (iHARP) database have helped to identify
the prevalence of critical inhaler errors (those that have
a definite detrimental impact on the delivery of drug to
the lungs) with different devices in patients with asthma
[18]. The most common critical errors included failure
to coordinate device actuation and inhalation with
pMDIs, and lack of a forceful inhalation with DPIs.
Breath-actuated inhalers (BAIs) represent an evolution
in inhalers’ design that may help to improve the man-
agement of asthma by reducing the likelihood of these
two critical inhaler errors occurring when DPIs and
pMDIs are used [19–22].
A novel, ergonomically designed breath-triggered in-
haler (BTI), k-haler®, has been developed to effectively
improve the delivery of inhaled therapies [23]. K-haler®
is not suitable to use with spacers; it produces a slow
aerosol plume and is not dependent on actuation-
inhalation coordination. Successful use of the k-haler®
involves only a few steps and, as an ‘active’ aerosol in-
haler, it automatically releases a dose of the drug in a
respirable form when the patient inhales, even at a low
inspiratory flow. As such, k-haler® represents an added-
value to improve asthma control by addressing current
patients’ needs and overcoming the most common last-
ing critical errors referred with pMDIs and DPIs.
Early history of inhaler devices
Inhalation therapy for respiratory diseases can be traced
back thousands of years, but it was later, in the nine-
teenth century, that most significant developments in in-
haler devices took place [24–26]. The first pressurized
inhaler was developed in 1858, and further advances in
inhalation therapy and inhaler design were achieved in
the early twentieth century [25–27]. The precursors of
modern inhalers emerged in the 1940s/1950s with the
development of the first commercial DPIs and pMDIs
[25–28].
Current DPIs and pMDIs: attributes, advantages
and disadvantages
Appropriate inhaler techniques vary according to each
device, particularly in the case of DPIs since each has its
own specific operation method. DPIs and pMDIs also re-
quire different inhalation techniques and specific breath-
ing patterns for optimal drug deposition in the lungs [1,
6, 28]. DPIs rely on the inspiratory force generated by
the patient, both to extract the powdered drug from a
reservoir or blister and to disaggregate the powder into
respirable particles (those with the potential to reach
and deposit in the lungs) [18]. By contrast, with pMDIs,
the drug (either in a solution or a suspension) is actively
expelled from a pressurized canister by a propellant, but
coordination of actuation and inhalation is required for
its effective delivery to the lungs [18].
A broad range of inhalers is nowadays available for the
treatment of asthma, thus the comparative analysis be-
tween all existing data is difficult. Although randomized
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controlled trials (RCTs) have not demonstrated any sig-
nificant differences in efficacy between device types,
most studies were designed to show non-inferiority or
equivalence between inhalers [6, 29]. Furthermore, in-
haler use in RCTs does not reflect the real-world, where
many patients use their inhalers incorrectly [5–9, 18].
Major issue: many patients do not use their
inhaler correctly
The inhaler technique is determinant to achieve asthma
symptoms control and a reduced risk of adverse outcomes.
Inhaler handling and inhalation error rates vary con-
siderably across studies, but high rates have been re-
ported for all device types [5, 7, 8, 30]. A study assessing
the inhaler technique in 66 individuals with asthma and
90 with Chronic Obstructive Pulmonary Disease
(COPD) found that 40% of the patients made at least
one potentially serious mistake when using their inhaler
device [8]. In an observational study by Melani and col-
leagues, encompassing 1633 patients who were regularly
using inhalers for the treatment of respiratory diseases
(asthma, n = 864; COPD, n = 703; other, n = 97), inhaler
errors were common with all device types studied, oc-
curring in 12% of patients using pMDIs and 35–44% of
those using DPIs (Diskus®, HandiHaler® and Turbuha-
ler®) [7]. In a systematic review of asthma and COPD
studies, the mean percentage of patients who could use
their inhaler without mistakes was 63% for pMDIs, 65%
for DPIs and 75% for BAIs [29].
However, higher frequencies of incorrect inhaler tech-
nique have been reported. Data from a retrospective, ob-
servational study of 3654 asthmatics that were enrolled
in iHARP showed that, overall, 89% of patients made at
least one potentially critical handling error and that 67%
made multiple potentially critical errors [18].
Incorrect inhaler technique is associated with
poor asthma control
Incorrect inhaler technique can significantly reduce the
amount of drug deposited in the lungs [10–12], and im-
pair drug effectiveness and safety [6, 7, 13–18]. In a pro-
spective observational study by Giraud and colleagues,
involving 727 patients with asthma, suboptimal inhaler
technique was significantly and independently associated
with poor asthma control (Asthma Control Question-
naire [ACQ] score ≥ 1.5; p = 0.008, 31]. Data from the
study by Melani and colleagues showed an association
between poor disease control, assessed by Asthma Con-
trol Test™ [ACT] scores, and risk of critical errors in in-
halation technique (odds ratio [standard error]; OR [SE]
1.53 [0.14]; p < 0.0001). Critical errors were also associ-
ated with increased hospital admissions (OR [SE] 1.47
[0.17]; p = 0.001), emergency department visits (OR [SE]
1.62 [0.20]; p < 0.001), and antibiotics (OR [SE] 1.50
[0.15]; p < 0.0001) and oral steroids use (OR [SE] 1.54
[0.16]; p < 0.0001, 7]. Different studies have also found
that a high frequency of inhaler errors was associated
with poorer asthma control, including an increase in the
frequency of exacerbations [31, 32]. In a real-world ob-
servational study of 3955 patients, 71% used their inhaler
incorrectly and, importantly, the number of errors in-
versely correlated with the level of asthma control (linear
regression analysis r = 0.3; p = 0.0001, 14].
The effect of handling and inhalation errors on asthma
control could result in a vicious cycle, wherein poor in-
haler technique leads to frequent symptoms and exacer-
bations, which in turn can then lead to reduced
adherence (Fig. 1). Reduced adherence can also contrib-
ute to an inadequate inhaler technique, due to less fre-
quent use and lack of training. HCPs often overestimate
the effectiveness of their patients’ inhaler technique [9],
therefore potentially compounding the problem by miss-
ing opportunities to help patients to improve their in-
haler technique.
The development of easy-to-use inhalers that are less
prone to inhalation technique errors remains a key clin-
ical need, from mild to severe disease, and including also
exacerbations. In addition, a better understanding of
which errors have the greatest potential to affect symp-
toms control would facilitate the development of im-
proved inhalers and/or training programs to overcome
these errors.
Identifying critical errors with DPIs and pMDIs
The nature and frequency of the different errors varies
between devices, as would be expected, given that each
device requires specific handling and inhalation
Fig. 1 The vicious cycle from inhalation errors to reduced adherence
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techniques [31]. Overall, inhalers with fewer steps to op-
erate may be less prone to errors [5]. This highlights the
need for easy-to-use inhalers that have only a few oper-
ational steps.
Errors can be categorized as either ‘critical’ or ‘non-
critical’ [5, 18, 33]. While there are several definitions of
critical errors, a review defined critical error as an action
or inaction that in itself would have a definite detrimen-
tal impact on the drug delivery to the lungs [32]. How-
ever, it should be stressed that the identification of
critical errors may be largely based on expert opinion
and information on the frequency of such errors and
their impact on asthma control is limited.
Data from the Critikal analyses of the iHARP database
have provided real-world insights into the types and fre-
quency of inhaler errors and their impact on asthma out-
comes: A cross-sectional study of 3660 patients with
asthma conducted between 2011 and 2014 identified spe-
cific inhaler handling errors associated with poor disease
control for Diskus®, Turbuhaler® and a pMDI, as well as
generic patient factors [18]. This data from the iHARP
analysis are consistent with previous studies showing that
failing to inhale with sufficient force from the start and
poor coordination of actuation and inhalation remain
common errors with DPIs and pMDIs, respectively.
Generic errors
In the Critikal analyses, the most common critical errors
were identified as being associated with all inhaler de-
vices (i.e. generic errors) [18]. More than a quarter of
patients did not breathe out to empty their lungs as
much as possible before inhalation (Diskus®, 32.4%; Tur-
buhaler®, 26.2%; pMDI, 25.4%). Patients making this
error were more likely to have uncontrolled asthma in
the previous week (as defined by the Global Initiative for
Asthma [GINA] guidelines) than those who did not
make the error (OR [95% confidence interval [CI] 1.48
[1.13–1.94], 1.27 [1.06–1.53] and 2.13 [1.57–2.89] for
Diskus®, Turbuhaler® and pMDI, respectively).
Another common mistake was not holding breath for
at least 3 s following inhalation (pMDI, 33.4%; Diskus®,
24.7%; Turbuhaler®, 22.1%). Insufficient breath-holding
was also associated with GINA-defined uncontrolled
asthma in the previous week (OR [95%CI] 1.77 [1.34–
2.35], 1.96 [1.46–2.63] and 1.53 [1.26–1.85] for pMDI,
Diskus® and Turbuhaler®, respectively).
DPI-specific errors
The Critikal analyses have also shown that an insuffi-
cient respiratory effort was one of the critical errors as-
sociated with uncontrolled asthma in patients using
either the Diskus® or Turbuhaler® DPI. In total, 38.4% of
patients using Diskus® and 32.1% of those using Turbu-
haler® did not inhale with sufficient inspiratory flow [18].
Multivariate logistic regression analysis demonstrated
that patients making this critical error with either Dis-
kus® or Turbuhaler® were more likely to have uncon-
trolled asthma in the previous week (as defined by
GINA) than those who did not make this error (Diskus®
adjusted OR [95%CI] 1.62 [1.23–2.14]; Turbuhaler® OR
[95% CI] 1.30 [1.09–1.54]; this association remained
after taking patient factors into consideration (Diskus®
OR [95%CI] 1.56 [1.17–2.07]; Turbuhaler® OR [95%CI]
1.30 [1.08–1.57]).
pMDI-specific errors
Not coordinating actuation and inhalation appropriately
(i.e. actuation occurring before inhalation) was a com-
mon error identified in 24.9% of the individuals using a
pMDI [18].
Multivariate logistic regression analysis showed that
patients who did not coordinate actuation with inhal-
ation correctly were more likely to have uncontrolled
asthma in the previous week (as defined by the GINA
guidelines) than those who performed this step correctly
(adjusted OR [95%CI] 1.43 [1.04–1.98]); this also
remained true after taking patient factors into consider-
ation (OR [95%CI] 1.55 [1.11–2.16]).
Although it is ideal for pMDI actuation and inhalation
to be coordinated, the requirement for split-second co-
ordination is not as critical as the most important aspect
of pMDI inhalation technique: to take a slow (< 60 L/
min) and deep inhalation, especially if the actuator has
been pressed after the inhalation has begun [34, 35].
Strengths and limitations of BAIs in asthma
management
BAIs are aerosol devices in a closed canister, that cannot
be contaminated, like pMDIs, but rather than being acti-
vated manually, they automatically release a dose of drug
when the patient inhales.
Despite BAIs limitations, namely to be available for a
limited range of drugs and the need to shake the suspen-
sion before each use, these devices may offer several ad-
vantages (Table 1).
BAIs were developed to overcome the most commonly
seen critical errors with other inhalers. There is no need
to coordinate actuation and inhalation (which is necessary
for pMDIs) and, as active devices, BAIs emit a propelled
aerosol and patients do not need to inhale forcibly to gen-
erate respirable particles (which is required for DPIs), be-
ing efficient with low inspiratory flow.
BAIs are associated with improved inhaler technique and
patient preference compared with other inhalers
BAIs are intended to simplify the inhaler technique,
leading to improved inhaler use by the patients and less
HCP time spent training patients to use the devices
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correctly [22]. Indeed, several studies have shown that
patients find BAIs easier to use and HCPs find it easier
to train patients in their correct use in relation to other
devices [9, 19, 36].
In an observational, real-life study encompassing 3811
individuals with asthma or COPD, the proportion of pa-
tients making at least one critical error with Autohaler®
(11%) was significantly lower than with other devices
such as a pMDI and the Turbuhaler® DPI (28 and 32%,
respectively; p < 0.05, 9].
In another study, a greater proportion of individuals
with asthma found Easi-Breathe® easier to use correctly
than a conventional pMDI (86% vs 14%, respectively;
n = 104) and nurses found it easier to train patients in
the use of the device (99% vs 1%, respectively; n = 104)
(p ≤ 0.001 for both comparisons) [19]. Moreover, 79% of
nurses preferred the BAI to pMDIs, with the main rea-
sons being ‘easier for patients to use correctly’ and ‘eas-
ier to teach’ (p ≤ 0.001). Most patients also expressed a
preference for Easi-Breathe® over pMDIs (82% vs 18%;
p < 0.001); ease of use and confidence in effective dose
delivery were stated as the key reasons for their
preference. The ease of use and consequent potential for
reduced training time with BAIs may be an important
advantage, especially given the limited time available in
typical primary care clinical consultations. The use of in-
halers with no adequate education can lead to more er-
rors, reduced therapeutic compliance and impaired
asthma control.
The Sirocco Study, including 6512 patients with
asthma, found that 91.4% were able to use the Autoha-
ler® without errors after a median training period of only
4 min, indicating that inhaler training would be feasible
in everyday clinical practice [36].
The ease of use of BAIs may offer particular advan-
tages in certain patient groups, such as children, elderly
or those with limited manual dexterity [21, 22, 37]. Easy-
to-use BAIs that are triggered by a low inspiratory force
may offer advantages [21, 22].
The ease of use and patient preference for BAIs may
translate into improved treatment compliance with the
prescribed therapy [20, 22]. However, this needs to be
assessed further with robust RCTs.
BAIs may help to improve asthma control
Some studies have suggested that use of BAIs may result
in improved lung function and asthma outcomes com-
pared with other devices [20–22, 38–41].
A study by Newman and colleagues assessed the effi-
cacy of the Autohaler® in 18 individuals with asthma
[38]. Patients who could not coordinate actuation and
inhalation with a pMDI (n = 8) achieved significant im-
provements in lung function with salbutamol when they
used the Autohaler® compared with the pMDI (p < 0.05).
Notably, however, lung function was not improved when
using the Autohaler® instead of the pMDI in the group
of patients with good coordination. Thus, besides dem-
onstrating the potential benefits of BAIs, these data also
show that pMDIs are successful airways delivery devices
when used correctly.
The clinical efficacy of different inhaler types was
assessed in a study in 51 elderly patients with asthma
(mean age 77.4 years). Among patients who had a poor
inhaler technique, improved clinical responses to salbu-
tamol were observed in most patients who were
switched from a pMDI to a BAI (n = 10/11), but not in
those who were switched from a pMDI to a DPI (n = 3/
10; p = 0.006). Further switching from a DPI to a BAI re-
sulted in improved inhaler technique in five out of seven
patients [39].
The SYSTER survey reported significant improve-
ments in asthma control and adherence after 4 weeks of
inhaled corticosteroids (ICS) therapy administrated via
the Autohaler® in 1510 patients with asthma (who were
either initiating therapy or were switched from another
device) [20]. After 4 weeks of therapy with the
Table 1 Advantages and disadvantages of breath-triggered
inhalers (BTIs)
Main advantage over pressurized metered dose inhalers (pMDIs)
There is no need to coordinate inhalation and actuation, since the
device is self-triggered by the patient’s inspiratory flow.
Main advantage over dry powder inhalers (DPIs)
BTIs release the drug at low inspiratory flow. Therefore, patients do
not need to inhale forcibly. Furthermore, drugs’ impact on upper
airways is reduced.
Further advantages of k-haler BTIs
The device is small, light and portable.
The device allows multiple doses, without any charging.
It has got a dose counter, so that patients know how many doses are
left.
Few steps are needed to prime and operate the device, making it
simple to use.
Audible “clicks” when priming and closing allow feedback that the
device is ready to use or store, respectively.
The automatic release of a dose when the mouthpiece cap is closed
prevents double or multiple doses if a primed dose is not taken.
The closed canister avoids contents’ contamination.
The cap is connected to the device, therefore it cannot be lost.
There is high reproducibility in the amount of drug delivered.
Main disadvantages
BTIs are available for a limited range of drugs.
If there is a suspension enclosed, patients need to remember to
shake the device before each use.
BTIs need priming before first use, in case of cold environment or if
not used for some time.
Legend: BTIs breath triggered inhalers, DPI dry powder inhalers, pMDI
pressurized metered dose inhalers
Morais-Almeida et al. Asthma Research and Practice             (2020) 6:4 Page 5 of 11
Autohaler®, asthma control had significantly improved
compared with baseline (mean [SD] ACQ score: 2.35
[1.05] at baseline vs 1.32 [0.93] at week 4; p < 0.0001).
Moreover, use of the Autohaler® was associated with sig-
nificantly increased patient-reported adherence, assessed
using the Morisky scale (mean [SD] score 2.11 [1.43] at
baseline vs 1.57 [1.53] at week 4; p < 0.0001), and satis-
faction with the inhaler, assessed using a visual analogue
scale (mean [SD] score 51 [19] at baseline vs 75 [14] at
week 4; p < 0.0001).
The reasons for these differences in outcomes between
inhaler types are unclear, but may relate to patient pref-
erence, improved adherence and/or better inhaler hand-
ling, all of which are reported advantages of BAIs. These
data highlight the potential benefits of having easy-to-
use devices such as BAIs available in clinical practice.
The k-haler®: a very unique BTI
The k-haler® is a recent BAI, and is also referred to as a
BTI [23]. This term emerged during the development of
the k-haler® ‘Instructions for use’, when it became appar-
ent that many patients did not understand the term ‘ac-
tuate’ or ‘actuation’, whereas they could easily relate to
the concept of the dose release being ‘triggered’ by inhal-
ation. This new term also ensures that the k-haler® is de-
scribed in a distinct way that clearly separates it from
conventional BAIs.
The k-haler® has won an award for its ease of use and
patient-focused design, requiring only a few steps to
achieve successful drug delivery [23]. This is an ‘active’
device that automatically releases a dose of the drug in a
respirable form when a patient inhales, even at a low in-
spiratory force (Table 1). Thus, this device significantly
helps patients to avoid failure to coordinate actuation
and inhalation (that is critical when using a pMDI), and
not inhaling with sufficient force to produce respirable
particles (essential when using a DPI).
Fluticasone propionate/formoterol (FP/FORM) k-
haler® contains the same drug components in the same
canister as the previous FP/FORM pMDI and it is cur-
rently approved for the treatment of adolescents (≥12
years) and adults with asthma [23].
Data from a prospective, cross-sectional survey of pa-
tients with asthma and their physicians in the USA sug-
gest that patients’ satisfaction with their inhaler is
associated with adherence to therapy, which may lead to
improved outcomes in asthma, namely control achieve-
ment [42]. With this in mind, k-haler® has several attri-
butes that may be favorable to patients and increase
acceptability of the device, from the shape and small
size, with the cap connected to the device, to the simpli-
city of use and the ease of reading the dose.
The innovative K-Valve with kinked-hose technology
forms the core of the k-haler® device. When the
mouthpiece cap of k-haler® is opened fully, the hose of
the K-Valve™ remains kinked (much like a kink in a
hose-pipe) and the valve remains closed (Fig. 2a). At the
same time, the canister stem is depressed, actuating the
device and allowing a single dose of the aerosolized drug
to enter the K-Valve™. The device is now primed; be-
cause the hose of the K-Valve™ is kinked, the drug is
held in this valve.
Catches on a flap inside k-haler® hold the K-Valve™ in
the closed position until the patient inhales. Inhalation
tilts the flap, which straightens the hose of the K-Valve™
(Fig. 2b), thus opening the valve and releasing the dose
through the mouthpiece.
Closing the mouthpiece cap resets the flap and K-
Valve™; if the patient does not inhale through the device,
the primed dose is released automatically when the
mouthpiece cap is closed, acting as a useful alert to the
patient that the device has not been triggered.
The patient friendly packaging for FP/FORM k-haler®
has been designed with clear, informative diagrams in
the patient information leaflet and also on the box for
maximum exposure; a Quick Response (QR) code allows
to access a demonstrative video. A series of web-based
training tools have also been developed to accommodate
the various learning styles and preferences of different
patients.
K-haler® is easy to use, with a simple procedure that
includes few steps [43]: shake; breathe out as slowly and
deeply as possible; holding the inhaler upright open the
orange mouthpiece cover fully and seal lips around the
mouthpiece; breathe in slowly and deeply; hold breath
for 5 s at least; remove the inhaler from the mouth and
close the cover.
Documentation of added therapeutic value and
place in the treatment of FP/FORM k-haler®
The added therapeutic value, from the public health per-
spective, is the result of comparisons between two or
more therapeutic options in order to identify innovation.
Innovation is present when a clearly identified, charac-
terized and validated health need is overcome (partially
or totally) by the availability of new technology.
As previously discussed, a significant barrier to an ef-
fective treatment of asthma is the inability of the patient
to properly use the inhalation device which leads to re-
duced adherence to treatment and asthma control.
The selection of the comparator medicinal product is
intended to document the added therapeutic value of
FP/FORM k-haler® in the regular treatment of asthma
when it is appropriate to use a drug with this combin-
ation (an ICS and a long-acting beta2-agonist (LABA)),
namely in GINA therapeutic steps three to five [1].
Containing the same drug components in the same
canister as FP/FORM pMDI, FP/FORM k-haler® would
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be expected to have similar characteristics, such as its
pharmacokinetic and pharmacodynamic properties, a
high fine particle fraction (FPF) and a plume that is less
forceful than that of previous pMDIs.
In a study that compared the plume force of FP/
FORM 125/5 μg K-haler®, fluticasone propionate/salme-
terol xinafoate 125/25 μg (FP/SAL) from the Seretide®
Evohaler® pMDI, and 125/25 μg FP/SAL from the Sirdu-
pla® pMDI, the FP/FORM K-haler® plume was 70–87%
less forceful than the Seretide® and Sirdupla® plumes, at
60 to 95 mm distances [44]. This can decrease drug im-
paction at the back of the throat and improve delivery to
the lungs.
K-haler®: ease of use and patient preference
The usability of k-haler® and patient preference for the
device compared with their current inhaler was assessed
in a randomized, open-label, observational crossover
study in 307 patients aged at least 12 years with asthma
(n = 199 [64.8%]), COPD (n = 86 [28.0%]) or asthma and
COPD (n = 22 [7.2%]) [45]. Individuals were stratified by
age (12–17 years, n = 66 [21.5%]; 18–65 years, n = 166
[54.1%]; > 65 years, n = 75 [24.4%]) and forced expiratory
volume in 1 s [FEV1] (< 60%, n = 87 [28.3%]; 60–80%,
n = 104 [33.9%]; > 80%, n = 116 [37.8%]). The primary
endpoint was successful device use (defined as the pro-
portion of patients who could perform all eight handling
and inhalation steps at their first attempt, using a pla-
cebo device). Secondary endpoints included the propor-
tions of patients who were able to generate sufficient
inspiratory force to trigger the k-haler® to release a dose,
who could successfully perform all ‘critical’ steps and
who expressed a preference for k-haler® over their
current device. The study showed that k-haler® was easy
to use, and that over three quarters of patients success-
fully triggered the device at their first attempt. Patients
also found the k-haler® inhalation technique easy to
learn. More than three-quarters of patients were able to
use k-haler® successfully at their first attempt. Almost
100% of patients could use the k-haler® correctly within
15min of initial training. At least 44% of patients found
k-haler® easier to use than their current maintenance
therapy device (compared with Symbicort® Turbuhaler®,
Seretide® Evohaler®, Seretide Accuhaler®/Diskus® and
Fostair® pMDI). Approximately 61–71% of patients pre-
ferred k-haler® to their current maintenance therapy in-
haler [45]. This study demonstrated that k-haler® can be
used successfully by patients with asthma, and that many
patients prefer k-haler® and find it easier to use than
their current device [42, 45].
FP/FORM k-haler® pulmonary bioavailability
The pulmonary bioavailability of FP/FORM k-haler® ver-
sus the FP/FORM pMDI was assessed in a single-dose,
randomized, open-label, crossover study in 47 healthy
adults [46]. The study was designed to demonstrate that
FP/FORM pulmonary bioavailability administered via
the k-haler® was no less than when administered via the
pMDI without a spacer. A charcoal block was used to
prevent gastrointestinal absorption of any swallowed
drug. Thus, plasma drug levels reflected uptake via the
lungs, and provided a surrogate pharmacokinetic esti-
mate of efficacy compared with that of the pMDI.
The FP/FORM pulmonary bioavailability administered
via the k-haler® was similar to the levels achieved when
administered via the pMDI without a spacer; hence, the
k-haler® would be expected to provide similar efficacy to
the pMDI [43–46].
When comparing FP/FORM k-haler® and FP/FORM
pMDI, the lower limits of the 94.12% CI for least-
squares (LS) geometric mean area under the curve over
time (AUCt), area under the curve to infinite time
(AUCINF) and maximum serum concentration (Cmax)
exceeded the pre-specified lower limit of 80%, indicating
similarity between the devices, when appropriate inhal-
ation techniques are ensured [46].
Furthermore, the concentration-time profiles for FP/
FORM were similar when administered via the k-haler®
Fig. 2 K-haler® K-Valve™ with kinked-hose technology
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and via the pMDI indicating similar regional pulmonary
bioavailability patterns. FP/FORM k-haler® was generally
well tolerated, with a similar adverse event profile to that
of FP/FORM pMDI [43, 46].
FP/FORM k-haler® total systemic bioavailability
The total systemic bioavailability of FP/FORM when ad-
ministered via the k-haler® and via the pMDI were
assessed in a single-dose, randomized, open label, cross-
over study in 48 healthy adults [47]. The primary object-
ive of the study was to assess the total systemic exposure
(as measured by Cmax, AUCt and AUCINF) of FP/
FORM administered via the k-haler® 125/5 μg (two puffs,
250/10 μg total dose) and the pMDI 125/5 μg (two puffs,
250/10 μg total dose), with and without a spacer.
The study demonstrated that the systemic bioavailability
of fluticasone propionate administered via the k-haler®
was not greater than when administered via the pMDI
with a spacer, and that the systemic bioavailability of for-
moterol administered via the k-haler® was similar to that
administered via the pMDI without a spacer [43, 47].
When comparing fluticasone propionate administered
via the k-haler® and via the pMDI with a spacer, the
upper limits of the 94.12% CI for LS geometric mean
AUCt, AUCINF and Cmax were below the pre-specified
safety threshold of 125%, indicating equivalent exposure
with the two devices [47].
For formoterol administered via the k-haler® and the
pMDI without a spacer, the upper limit of the 94.12% CI
for AUCt, and AUCINF ratios were below the pre-
specified safety threshold of 125%; however, the corre-
sponding value for Cmax was narrowly outside this
threshold (125.97%).
Because the exposure of formoterol administered via
the k-haler® was greater than that via the pMDI without
a spacer, the study was extended to include pharmaco-
dynamics assessments of formoterol-mediated effects, in
order to definitely confirm the safety of the formoterol
component in FP/FORM k-haler®.
These further analyses demonstrated that the k-haler®
was equivalent to the pMDI with a spacer for maximum
reduction in serum potassium (ratio [95%CI] 0.97 [0.73–
1.28]; primary endpoint). These data confirm that the
formoterol-related systemic safety of FP/FORM k-haler®
is similar to that of FP/FORM pMDI [43, 47].
FP/FORM k-haler® scintigraphy study and lung deposition
FP/FORM k-haler® and FP/FORM pMDI are expected to
produce similar lung deposition when used correctly.
Previous studies using in vitro functional respiratory im-
aging have suggested that FP/FORM pMDI provides
drug lung deposition of up to 44% of the metered dose
in patients with asthma (based on modelled data) [48],
which is notably greater than that seen with other ICS/
LABA combinations using the same methodology [49,
50].
A recent study assessed the in vivo lung deposition of
FP/FORM k-haler® using scintigraphy [51]. Following
training on how to use the k-haler® correctly, a total of
36 healthy volunteers, patients with asthma (GINA step
2 or higher, FEV1 ≥ 60% and ≤ 90% predicted) and pa-
tients with COPD (FEV1 of ≥30% and ≤ 50% predicted)
(12 individuals in each group) inhaled a radiolabeled
(99mTc) suspension of FP/FORM via k-haler®.
FP/FORM k-haler® provided high levels of mean (SD)
lung deposition of 44.7% (14.2) in patients with asthma,
and of 39.0% (13.0) and 26.6% (8.0) in patients with
COPD and healthy volunteers, respectively. This demon-
strates that the k-haler® is associated with efficient drug
delivery in vivo that is similar to the modelled lung de-
position observed with FP/FORM pMDI [43, 51].
Importantly, the study showed that lung deposition
with FP/FORM k-haler® is not affected by airflow limita-
tion; the increased lung deposition observed in patients
with asthma or COPD compared with healthy volunteers
is probably due to these patients having real-life experi-
ence in using inhalers [51].
Analysis of economic value
Adult asthma represents a very significant load of total
health expenditure [52]. A considerable proportion is re-
lated to the treatment of asthma in uncontrolled pa-
tients, since in these cases direct costs are twice as
expensive as the cost of treatment in controlled patients
[53]. Therefore, therapeutic alternatives with a lower
price and that reduce the direct costs to the health sys-
tems (costs related to exacerbations, hospitalizations,
time spent by HCP) have an economic advantage [54].
In our country, the market price of FP/FORM K-
haler®, the first BTI class inhaler containing an ICS/
LABA association for the treatment of asthma, allows an
economic advantage. This results from a lower price
compared to the available direct alternative, as well as
from other significant economic advantages that can re-
sult from the reduction of risks related to handling er-
rors with the use of inhalers and the reduction of the
time that the HCP needs to spend to educate / train the
patient to use the inhaler correctly [33, 55].
Using the data from the Critikal study [18], Forsters
et al. explored the cost-effectiveness of an error-targeted
intervention related with DPI, using a probabilistic
Markov cost-utility model, with simulated patients tran-
sitioning between controlled and uncontrolled health
states over 1 year. The analysis explored complete/par-
tial eradication of the error when the intervention was
priced to match comparators, as well as impact of indir-
ect costs based on lost/reduced productivity. This study
demonstrated the economic and societal costs of
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‘insufficient inspiratory effort’ and potential economic
benefits of introducing an effective intervention to re-
duce/eradicate this error related with DPIs [56]. Thus,
this analysis reinforced that inefficient use of inhalers
have significant economic consequences.
Conclusions
The development of easy-to-use inhalers that are less
prone to inhalation technique errors remains a key
clinical need in respiratory diseases, such as asthma
or COPD. BTI R&D brings innovation with advantage
over current available inhalers, avoiding the two most
common identified critical errors in inhalation
technique.
The latest BTI FP/FORM k-haler® contains the same
drug components in the same canister as FP/FORM
pMDI. It shares many of the same characteristics as
the pMDI, such as a high FPF and favorable plume
characteristics. Pharmacokinetic studies have shown
that FP/FORM k-haler® provides a drug delivery simi-
lar to FP/FORM pMDI (with and without a spacer),
whether assessed by pulmonary or total systemic ex-
posure, demonstrating that the two devices are thera-
peutically equivalent. Moreover, many patients find k-
haler® easier to use than their current device and ex-
press a preference for this inhaler. These data are im-
portant because patient inhaler satisfaction may be
correlated with treatment adherence and improved
outcomes in asthma.
High levels of lung deposition have been demonstrated
with FP/FORM k-haler® use, highlighting its efficient
drug delivery. This inhaler has an attractive design,
which has already been awarded. It is simple to use from
the first attempt and it is accompanied by appealing ma-
terials to support its correct use, accessible either in the
handling of an on-site demonstration kit of the prescrip-
tion (k-trainer), or in the package leaflet, as well as those
that are available interactively on the web.
This compact inhaler of reduced size, easy to handle
and use, is also suitable for asthmatics with orthopaedic
degenerative diseases of the hands. A color-coded front
dose meter facilitates asthma management and alerts to
the need for inhaler renewal.
In daily practice, on “the real world”, educational mea-
sures remain essential, always repeating the cycle: to
know, to show, to educate (shake, open, inhale, close), to
check and correct any handling or inhalation errors in
every medical appointment, and not only in the first
clinical consultation. Not only medical doctors but also
nurses, pharmacists, lung technicians, the whole health-
care team is called into action to guarantee a continuous
successful treatment. If correctly used, inhalers are ex-
cellent, safe and effective in controlling asthma. Patients’
preferences should always be respected.
FP/FORM k-haler® simplifying procedures with cost
reduction, is already available as a relevant contribution
to increase treatment adherence and to facilitate asthma
control in adolescents and adults, where treatment with
an ICS/LABA association is indicated.
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